tiprankstipranks
Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
US Market

Knight Therapeutics (KHTRF) Stock Forecast & Price Target

Compare
33 Followers
See the Price Targets and Ratings of:

KHTRF Financial Forecast

KHTRF Earnings Forecast

Next quarter’s earnings estimate for KHTRF is $0.01 with a range of -$0.02 to $0.04. The previous quarter’s EPS was $0.00. KHTRF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.02% of the time in the same period. In the last calendar year KHTRF has Preformed in-line its overall industry.
Next quarter’s earnings estimate for KHTRF is $0.01 with a range of -$0.02 to $0.04. The previous quarter’s EPS was $0.00. KHTRF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.02% of the time in the same period. In the last calendar year KHTRF has Preformed in-line its overall industry.

KHTRF Sales Forecast

Next quarter’s sales forecast for KHTRF is $61.80M with a range of $58.30M to $64.15M. The previous quarter’s sales results were $65.04M. KHTRF beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.77% of the time in the same period. In the last calendar year KHTRF has Outperformed its overall industry.
Next quarter’s sales forecast for KHTRF is $61.80M with a range of $58.30M to $64.15M. The previous quarter’s sales results were $65.04M. KHTRF beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.77% of the time in the same period. In the last calendar year KHTRF has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus
$4.41
Buy
11.54%
Upside
Reiterated
11/18/24
Stifel Nicolaus Keeps Their Buy Rating on Knight Therapeutics (KHTRF)
Raymond James
$5.64$5.29
Buy
33.85%
Upside
Reiterated
11/14/24
Knight Therapeutics price target lowered to C$7.50 from C$8 at Raymond JamesKnight Therapeutics price target lowered to C$7.50 from C$8 at Raymond James
Bloom Burton
$6.34
Buy
60.62%
Upside
Reiterated
11/08/24
Knight Therapeutics: Strong Revenue Growth and Strategic Prospects Justify Buy Rating
Research Capital
$4.58
Hold
16.00%
Upside
Downgraded
11/07/24
Knight Therapeutics downgraded to Hold from Buy at Mackie Research CapitalKnight Therapeutics downgraded to Hold from Buy at Mackie Research Capital
RBC Capital
$4.93
Buy
24.93%
Upside
Reiterated
11/07/24
Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD), Knight Therapeutics (Other OTC: KHTRF) and OnKure Therapeutics (NASDAQ: OKUR)
Canaccord Genuity
$5.11
Buy
29.39%
Upside
Initiated
04/15/24
Knight Therapeutics resumed with a Buy at CanaccordKnight Therapeutics resumed with a Buy at Canaccord
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Knight Therapeutics

Which Analyst Should I Follow If I Want to Buy KHTRF and Sell After:
1 Month
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+2.13%
initiated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +2.13% per trade.
3 Months
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+0.52%
initiated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +0.52% per trade.
1 Year
Douglas MiehmRBC Capital
Success Rate
8/19 ratings generated profit
42%
Average Return
-3.63%
reiterated a buy rating 4 months ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -3.63% per trade.
2 Years
xxx
Success Rate
8/19 ratings generated profit
42%
Average Return
-4.31%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.11% of your transactions generating a profit, with an average return of -4.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KHTRF Analyst Recommendation Trends

Rating
Mar 24
Apr 24
May 24
Aug 24
Nov 24
Strong Buy
5
5
7
8
12
Buy
0
0
0
0
0
Hold
1
1
2
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
9
10
15
In the current month, KHTRF has received 12 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KHTRF average Analyst price target in the past 3 months is $4.41.
Each month's total comprises the sum of three months' worth of ratings.

KHTRF Stock Forecast FAQ

What is KHTRF’s average 12-month price target, according to analysts?
Based on analyst ratings, Knight Therapeutics’s 12-month average price target is $4.41.
    What is KHTRF’s upside potential, based on the analysts’ average price target?
    Knight Therapeutics has 11.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KHTRF a Buy, Sell or Hold?
          Knight Therapeutics has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Knight Therapeutics’s price target?
            The average price target for Knight Therapeutics is $4.41. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $4.41 ,the lowest forecast is $4.41. The average price target represents 11.65% Increase from the current price of $3.95.
              What do analysts say about Knight Therapeutics?
              Knight Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of KHTRF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis